Dallas-based Forte Biosciences is cashing in, with argenx agreeing today to buy the local biotech for roughly $2.2 billion in cash in a deal that instantly turns an experimental antibody into a marquee asset.
The offer comes in at $77 a share and centers on FB102, Forte’s first-in-class anti-CD122 antibody that argenx plans to plug straight into its growing immunology pipeline through a cash tender offer.
Deal Terms and Price
In a press release, argenx said it will pay $77 per share, valuing Forte at about $2.2 billion. The company said that price represents roughly an 86% premium to Forte’s volume-weighted average price since the biotech reported positive Phase 1b data.
The boards of both companies have signed off on the transaction. argenx says it will fund the buyout from cash on hand and that the offer is not subject to a financing condition. Under the merger agreement, argenx will launch a cash tender offer, and the deal will only close if a majority of Forte shares are tendered and the Hart-Scott-Rodino waiting period expires, according to StreetInsider.
FB102 and the Clinical Case
FB102 is a first-in-class anti-CD122 monoclonal antibody that Forte has been testing in vitiligo and celiac disease. The company reported statistically significant Phase 1b results in vitiligo on July 9, a milestone that appears to have sparked the surge of buyer interest.
Coverage of the transaction has highlighted FB102’s potential in alopecia areata and other autoimmune indications as a central part of the rationale for the bid, as reported by Bloomberg. In other words, argenx is paying up not just for early vitiligo data, but for the broader autoimmune upside it sees in the mechanism.
Dallas Ties
Forte is firmly rooted in Dallas. The company is headquartered at Pegasus Park, the city’s fast-growing life sciences hub, and has advanced FB102 out of facilities in the Pegasus Park business complex.
Forte’s SEC filings list its principal business address as 3060 Pegasus Park Drive, Building 6, Dallas, TX 75247, according to filings with the U.S. Securities and Exchange Commission. Local outlets have been tracking the company’s fundraising and early-stage progress for years as it quietly built the program that is now at the center of a multibillion-dollar deal, with Dallas Innovates among those chronicling its financing and footprint in the city’s biotech scene.
Why Argenx Bought In
For argenx, FB102 offers a way to go after pathogenic T-cell and NK-cell activity, giving the company another immunology lever to pull. That fits neatly alongside its existing antibody-based medicines such as efgartigimod, which already anchor the company’s portfolio.
argenx has a sizable global development operation, including U.S. operations based in Boston, a setup that its investor materials and reporting describe as key to scaling new programs. FB102 now joins that machine, with argenx betting that dialing down overactive immune cells will slot cleanly into its broader strategy.
Market Reaction and Background
Traders did not wait around. Markets reacted quickly after the announcement, with reports of sharp trading in Forte shares as investors processed the premium baked into the $77 offer. Early market write-ups captured the jump in FBRX stock and the ensuing commentary around the valuation, per Investing.com.
The deal also follows an earlier strategic investment by argenx in Forte, which was disclosed in Forte’s SEC filings tied to an April financing. That prior stake now looks like a shrewd warm-up act for a full takeover.
What’s Next
Next up is paperwork and waiting. argenx said it will file tender offer materials with the SEC and expects the transaction to close in the third quarter of 2026, subject to customary closing conditions and regulatory review.
In the companies’ announcement, Argenx CEO Karen Massey framed the deal as part of a bigger play in immune diseases, saying the acquisition “builds on the strength of that foundation and advances our ambition to be the leading immunology innovator of the future.” If the tender offer and regulators cooperate, Dallas will have quietly handed off one of its homegrown biotechs in a multibillion-dollar exit.
